Investment and financing｜Investment and financing analysis report in the field of high-value consumables in 2022
Financing overview
From 2017 to 2021, from the point of view of the number of financings, the number of financing trends in the field of high-value consumables in China is as follows, the total number of financing was 744, an average of about 148 per year, and the total number of financing in the field of high-value consumables in 2022 was 143, down 34.7% from last year.
Figure 1 Financing situation in the high-value consumables sector, 2017-2022
From the perspective of financing rounds, the number of “angel round” financing events for high-value consumables in 2022 was 11 times, the number of “Round A (including pre-A round, etc.)” financing events was 38 times, the number of “Round B (including pre-B round, etc.)” financing events was 21 times, and the number of “Round C (including pre-C round, etc.)” financing events was 8 times. The number of “D series (including pre-D series, etc.)” financing events was 7 times, the number of “Pre-IPO” financing events was 1 time, the number of “strategic investment and financing” financing events was 36 times, the number of “IPO” financing events was 8 times, and the number of “other” financing events was 13 times.
Analysis of the subdivision of mechanical enterprises
In 2022, the segmented areas of the equipment enterprises that obtained financing for the high-value consumables track are concentrated as follows：In 2022，the number of financing events for “Single/multi-component memory alloy bone fixation device” was 2，the number of financing events for “Smooth or threaded metal bone fasteners” was 2, the number of financing events of “Injection materials for plastic surgery” was 2 times，the number of “Spinal interbody fixation/replacement system” financing events was 2, the number of financing events for “Soft tissue repair and reconstruction implant for sports Injury” was 3，the number of “Guiding conduit” financing events was 3, the number of “Interbody fusion device” financing events was 3, the number of “Implantable cycle AIDS” financing events was 4，the number of “Intraocular lens” financing events was 4, the number of “microconduit” financing events was 4, the number of “guidewire” financing events was 4, the number of” Balloon dilatation catheter” financing events was 5, the number of “Vascular stent” financing events was 5, the number of financing events for “Artificial heart valves and valve repair devices” was 13.
Financing Analysis of Machinery Enterprises in Various Cities
In 2022, the machinery enterprises that obtained financing for high-value consumables track were mainly distributed in Shenzhen, Shanghai, Beijing, Hangzhou, Suzhou, Xi’an, Jiaxing, Ningbo, Changzhou and Guangzhou.
Regional Distribution of Low Value Consumable Machinery Enterprises Obtaining Financing for High Value Consumables in 2021 VS 2022 (piece)
Details of investment and financing
| Serial Number |
Financing Enterprise |
Investment Enterprise |
Financing Round | Financing Amount | Financing Time | Grade 1 Circuit | Grade 2 Circuit |
| 1 | Fosunpharma | Jpmorgan, Huatai Futures, Chinaamc,,UBS, Guotai Junan Securities Asset Management,
Perseverance Asset Management, Caitong Fund Management，China Merchants Fund，CITIC Fund，Dacheng Fund |
Private Placement | RMB 4.456 billion | 7/27/2022 | Medical consumable | High value
consumable |
| 2 | Caina Med | public issue | IPO | RMB 1.183 billion | 1/26/2022 | Medical consumable | High value
consumable |
| 3 | High Vision Medical Investment | public issue | IPO | RMB 672 million | 12/12/2022 | Medical consumable | High value
consumable |
| 4 | Decans Med | lanson，Capital Securities，HBVC Group,etc. | Round B | RMB 500 million | 2/21/2022 | Medical consumable | High value
consumable |
| 5 | Smartee(Shanghai) | Taikang Investment, CR Capital，ZHANGJIAGANG
Industrial Investment，Jiaxing Science City, |
Round D | RMB 500 million | 3/20/2022 | Medical consumable | High value
consumable |
| 6 | Zhejiang Smartee | Taikang Investment, CR Capita，Jiaxing Science City，Zhangjiagang Industrial Capital Center，Yuanbio Venture Capital ，Hongrui Investment，Howbuy, | Round D | RMB 500 million | 3/20/2022 | Medical consumable | High value
consumable |
| 7 | Suzhou Sceneray | Hillhouse Capital，Sequoiacap, | Round D+ | RMB 300 million | 2/16/2022 | Medical consumable | High value
consumable |
| 8 | MicroPort NeuroTech | public issue | IPO | HKD 338 million | 7/15/2022 | Medical consumable | High value
consumable |
| 9 | Beijing yierkangbio. | Bloomage Bioactech. | M&A | RMB 233 million | 4/20/2022 | Medical consumable | High value
consumable |
| 10 | Kai Medtech | SCGC，Lingang Sc-inovation Invest.Zhangjiang Haoheng, Shanghai Sci-Tech Innovation Center Capital，Betta Pharma. Hengxu Capital | Round B+ | RMB 2 hundred Million | 3/11/2022 | Medical consumable | High value
consumable |
| 11 | Rain Med | public issue | IPO | HKD 146 million | 7/8/2022 | Medical consumable | High value
consumable |
| 12 | Shenzhen Core Medical Technology | CoStone Capital ，GL Ventures，New Alliance Capital，Nanshan SEI Investment，Beihang Investment，Shenzhen Xinlitai Medical Devices， | Round B | Hundreds of millions of RMB | 12/30/2022 | Medical consumable | High value
consumable |
| 13 | .Trausim | MF Capital, Sunho Capital, | Round A | Hundreds of millions of RMB | 11/8/2022 | Medical consumable | High value
consumable |
| 14 | Kossel Medtech (Suzhou) | Mingbio Ventures, IN CAPITAL | Round A | Over 100 million RMB | 1/1/2022 | Medical consumable | High value
consumable |
| 15 | Sonosemi | Tencent Investment, Alwin Capital, Shanghai Fu Rong Investment，Eight Roads, Ruijian Investment， Jiuzhixinfei |
Round A | Hundreds of millions of RMB | 4/12/2022 | Medical consumable |
High value consumable |
Data Source：MDCLOUD
Data declaration:
Data dimension: Investment and financing data of domestic medical device R&D and production enterprises, including: financing time, financing events, financing scale, financing rounds, investment institutions, segments, cities. (Since the amount of financing was not disclosed in some cases, this paper will maximize the realistic significance reflected by the data based on limited information.)analytical category
statistical time：January 1, 2017 – December 31, 2022
Statistical range: high value consumables
China is encouraging China end uses for more domestic products in latest years. Thus, more and more overseas manufacturers are planning localization in China. BradyKnows localization team has extensive experiences in facility establishment, audit, supplier evaluation, manufacturing, registration, and marketing in China. Pls feel free to let us know any questions on China entry via info@bradyknowsmedical.com
Source：MDCLOUD
Translated & edited ： Bradyknows
